Forward to: Clinical Operations

Clinical Trial
Monitoring Workflows

Ten agent workflows for Clinical Operations -- trial registry monitoring, CRO performance benchmarking, patient enrollment intelligence, endpoint analysis, site selection optimization, protocol amendment tracking, regulatory submission monitoring, data readout prediction, clinical operations cost intelligence, and clinical trial dashboard -- enabling faster, smarter clinical development powered by comprehensive domain intelligence.

These workflows display realistic demo data for demonstration. In production, the agents connect to your real pharmaceutical data via MCP services or CSV import.
Deployment Options
The entire platform is available as a self-hosted solution or managed service
Self-Hosted
RECOMMENDED FOR ENTERPRISE
Deploy the entire platform on your own infrastructure. Your data never leaves your environment. Bring your own LLM API key (OpenAI, Claude, Gemini) or use local LLMs. Full source code delivered.
Complete source code (Python agents, PHP dashboards, MCP services)
Data stays on your servers — no external data transfer
MCP connectors for clinical trial, regulatory, and research databases
Custom integration and onboarding support available
$999
2 AI Agents
5 integration hrs
$1,999
5 AI Agents
10 integration hrs
$3,999
10 AI Agents
20 integration hrs
one-time license + (optional) $999/yr updates
Managed Platform
FOR AGENCIES & TEAMS
We host and operate the platform for you. Upload data or connect your platforms via secure MCP services or using API. No infrastructure management needed.
Fully managed — no DevOps required on your side
Secure data upload or API-based MCP integration
Dashboard access with your own branded login
Automatic updates and new agent releases
$999/mo
2 AI Agents
5 integration hrs
$1,999/mo
5 AI Agents
10 integration hrs
$3,999/mo
10 AI Agents
20 integration hrs
includes hosting, updates & support
* price may be higher in cases of very high AI processing volumes/demands
Both options include MCP services with connectors for clinical trial, regulatory, and research databases. Data dictionaries define the schema contract between each agent and your data sources.
See example of production dashboards: Programmatic Trading AI Agent Dashboards →

1Trial Registry Monitoring

AI agent monitors clinical trial registries and competitor press pages to detect new trial initiations, protocol amendments, and status changes across therapeutic areas of interest.

1
Detect New Trial Registrations
/press/products/investorsOpenPageRank
TRIAL REGISTRY INTELLIGENCE — ONCOLOGY ════════════════════════════════════════════════════════ NEW REGISTRATIONS THIS WEEK: merck.com: NCT06284501 Phase III — Keytruda + V940 (mRNA vaccine) in melanoma Primary endpoint: RFS | Est. enrollment: 1,100 | 340 sites roche.com: NCT06291847 Phase II — Tiragolumab + Tecentriq in HCC Primary endpoint: ORR | Est. enrollment: 450 | 120 sites astrazeneca.com: NCT06302115 Phase III — Dato-DXd vs docetaxel in NSCLC Primary endpoint: OS | Est. enrollment: 860 | 280 sites STATUS CHANGES: Terminated: BMS NCT05891234 — TIM-3 inhibitor Phase II Suspended: Gilead NCT05743901 — clinical hold Completed: Lilly NCT05234892 — orforglipron Phase III Weekly summary: 47 new registrations | 8 terminations | 12 completions

2CRO Performance Benchmarking

AI agent monitors CRO capabilities, client relationships, and trial execution metrics by tracking CRO domain content including case studies, capabilities pages, and partnership announcements.

1
Benchmark CRO Capabilities
/products/press/case-studies/careersOpenPageRank
CRO PERFORMANCE INTELLIGENCE ════════════════════════════════════════════════════════ TIER 1 CROs — CAPABILITY UPDATES: iqvia.com /products: AI-powered patient matching launched /careers: +1,200 data science roles posted /case-studies: 98.2% site activation on-time rate SIGNAL: Investing heavily in decentralized trial capabilities ppd.com (Thermo Fisher) /products: Accelerated oncology enrollment program /press: 34% faster enrollment in rare disease trials SIGNAL: Rare disease and oncology specialization deepening iconplc.com /products: Decentralized trial platform v3.0 /press: 15 new sponsor partnerships announced /careers: Restructuring signal — 400 positions consolidated SPECIALTY CROs: medpace.com: Mid-size biotech focus — backlog $2.8B syneos.com: Commercial-integrated model — under review parexel.com: Regulatory expertise — FDA submission success 96%

3Patient Enrollment Intelligence

AI agent analyzes enrollment dynamics across competitor trials by monitoring recruitment status changes, site activation timelines, and enrollment completion announcements.

1
Track Enrollment Dynamics
/press/investors/productsOpenPageRank
ENROLLMENT INTELLIGENCE — COMPETITIVE TRIALS ════════════════════════════════════════════════════════ ENROLLMENT COMPETITION — OBESITY TRIALS: lilly.com: Orforglipron Phase III (4 trials) Total target: 8,400 patients across studies Status: 62% enrolled — competing for same population novonordisk.com: CagriSema Phase III Total target: 3,200 patients Status: Enrollment complete — ahead of Lilly amgen.com: MariTide Phase III Total target: 4,000 patients Status: 45% enrolled — site overlap concerns ENROLLMENT BOTTLENECKS DETECTED: Alzheimer's (anti-amyloid): Amyloid PET screening failing 65% NASH: Biopsy requirement limiting enrollment by 40% Rare disease (gene therapy): Natural history run-in extending timelines ALERT: 7 competitive trials competing for GLP-1 naive patients

4Endpoint & Outcome Analysis

AI agent monitors clinical trial endpoints, interim analysis announcements, and topline result disclosures to assess competitive program success rates and outcome trends.

1
Analyze Trial Outcomes
/press/investors/docsOpenPageRank
ENDPOINT & OUTCOME INTELLIGENCE ════════════════════════════════════════════════════════ POSITIVE READOUTS THIS MONTH: lilly.com: Tirzepatide SURMOUNT-OSA /press: AHI reduction 62.8% — met primary endpoint SIGNAL: Sleep apnea becomes 3rd major tirzepatide indication astrazeneca.com: Dato-DXd TROPION-Lung02 /press: ORR 56% combo vs 29% chemo — highly significant SIGNAL: ADC + IO combo paradigm gaining evidence base NEGATIVE/MIXED READOUTS: bms.com: Cendakimab Phase III UC /press: Did not meet co-primary endpoint SIGNAL: IL-13 pathway in UC disappointing — competitive advantage to IL-23 ENDPOINT TRENDS: Surrogate endpoints gaining FDA acceptance: ctDNA-MRD, pCR Novel PRO endpoints: Digital biomarkers in 14% of new trials Composite endpoints: Increasing complexity — adjudication challenges

5Site Selection Optimization

AI agent analyzes clinical trial site performance data, investigator experience signals, and regional enrollment capacity to optimize site selection for new studies.

1
Optimize Site Network
/about/products/pressOpenPageRank
SITE SELECTION INTELLIGENCE ════════════════════════════════════════════════════════ SITE NETWORK ANALYSIS — ONCOLOGY: Top-enrolling academic medical centers: mdanderson.org: 347 active trials — highest density mskcc.org: 312 active trials — strong Phase I dana-farber.org: 289 active trials — hematology leader REGIONAL CAPACITY: US sites: High competition — 12 obesity trials per top site EU sites: Available capacity — 30% fewer competing trials Asia-Pacific: Japan regulatory alignment improving enrollment feasibility SITE PERFORMANCE SIGNALS: Dedicated research sites (non-academic): sarahcannon.com: 42% faster activation than academic average horiresearch.com: Oncology screening rate 2.3x national average RED FLAG: 34% of US sites overcommitted — enrollment competition risk RECOMMENDATION: Expand Eastern EU and APAC site footprint

6Protocol Amendment Tracking

AI agent detects protocol amendments in competitor trials by monitoring registry updates, press disclosures, and investor communications that signal trial design changes.

1
Detect Protocol Changes
/press/investors/docsOpenPageRank
PROTOCOL AMENDMENT INTELLIGENCE ════════════════════════════════════════════════════════ SIGNIFICANT AMENDMENTS DETECTED: sarepta.com: SRP-9001 (gene therapy, DMD) Amendment: Primary endpoint changed from NSAA to micro-dystrophin /investors: FDA guidance on functional endpoints SIGNAL: Endpoint change suggests enrollment or efficacy challenge biogen.com: BIIB080 (tau ASO, Alzheimer's) Amendment: Sample size increased from 400 to 700 /press: Powered for subgroup analyses SIGNAL: Sponsor confidence — investing in larger study alnylam.com: Vutrisiran HELIOS-B Amendment: Expanded inclusion criteria — broader ATTR population /press: Accelerating enrollment with broader patient base SIGNAL: Positive interim data enabling expansion AMENDMENT PATTERNS: Endpoint changes: 18 this quarter (often signals difficulty) Sample size increases: 24 (can signal underpowering or confidence) Inclusion broadening: 31 (typically positive — expanding market)

7Regulatory Submission Monitoring

AI agent tracks regulatory submission timelines by monitoring NDA/BLA filing announcements, priority review designations, and PDUFA date assignments from competitor press pages and FDA portals.

1
Track Regulatory Milestones
/press/investors/complianceOpenPageRank
REGULATORY SUBMISSION TRACKER — 2026 ════════════════════════════════════════════════════════ UPCOMING PDUFA DATES: lilly.com: Orforglipron (oral GLP-1, obesity) PDUFA: June 2026 — Priority Review granted SIGNAL: First oral GLP-1 — potentially transformative approval pfizer.com: Danuglipron (oral GLP-1, obesity) PDUFA: September 2026 — Standard Review SIGNAL: Second-mover — differentiation unclear astrazeneca.com: Dato-DXd (TROP2 ADC, NSCLC) PDUFA: April 2026 — Priority Review NEW SUBMISSIONS FILED: vertex.com: Suzetrigine (pain, Nav1.8) /press: NDA accepted — non-opioid analgesic regeneron.com: Dupixent (COPD sBLA) /press: sBLA filed for new COPD indication DESIGNATIONS: Breakthrough Therapy: 14 new designations this quarter Accelerated Approval pathway: FDA tightening confirmatory requirements

8Data Readout Prediction

AI agent predicts upcoming data readout windows by analyzing trial start dates, enrollment completion signals, estimated primary completion dates, and conference calendar alignment.

1
Forecast Data Catalysts
/investors/press/eventsOpenPageRank
DATA READOUT PREDICTIONS — NEXT 90 DAYS ════════════════════════════════════════════════════════ HIGH-IMPACT READOUTS (market-moving): novonordisk.com: CagriSema Phase III (REDEFINE 1) /investors: "Topline expected H1 2026" Conference: ENDO 2026 abstract submitted — likely venue SIGNAL: $30B+ peak revenue asset — highest impact readout of H1 merck.com: V940 + Keytruda Phase III (melanoma) /investors: "Data expected mid-2026" Conference: ASCO 2026 late-breaking window SIGNAL: mRNA cancer vaccine — could reshape immuno-oncology biogen.com: BIIB080 (tau ASO, Alzheimer's) /investors: "Phase II topline H2 2026" SIGNAL: First anti-tau readout — mechanism validation event CONFERENCE CATALYST CALENDAR: ASCO (June): ~35 Phase III readouts expected EASL (June): NASH readouts from 4 programs ADA (June): Oral GLP-1 head-to-head data

9Clinical Operations Cost Intelligence

AI agent benchmarks clinical trial costs by monitoring CRO pricing signals, site cost disclosures, and regulatory fee changes to optimize clinical development budgets.

1
Benchmark Clinical Trial Costs
/investors/press/pricingOpenPageRank
CLINICAL OPERATIONS COST INTELLIGENCE ════════════════════════════════════════════════════════ CRO PRICING TRENDS: Full-service Phase III (oncology): $45K-$65K per patient (+12% YoY) Full-service Phase III (cardiometabolic): $28K-$42K per patient Decentralized trial premium: +15-25% over traditional iqvia.com: /investors disclosed backlog margin expansion iconplc.com: /investors reported pricing power improving SIGNAL: CRO pricing power at decade high — budget pressure SITE COSTS BY REGION: US academic: $38K per patient (highest globally) US community: $22K per patient Western EU: $18K per patient Eastern EU: $9K per patient — best value for global trials Asia-Pacific: $7K per patient — quality improving rapidly COST OPTIMIZATION SIGNALS: Adaptive designs reducing sample sizes 15-20% Real-world data integration cutting Phase IV costs 30% FDA user fees increasing 8% — PDUFA VII implementation

10Clinical Trial Dashboard

AI agent synthesizes all clinical trial intelligence into a consolidated dashboard tracking competitive trials, enrollment dynamics, readout calendars, and regulatory milestones.

1
Synthesize Clinical Intelligence
/investors/press/products/eventsOpenPageRank
CLINICAL TRIAL DASHBOARD — Q1 2026 ════════════════════════════════════════════════════════ TRIAL LANDSCAPE OVERVIEW: Total trials monitored: 4,287 across 68 competitor domains New registrations this quarter: 547 Completions: 198 Terminations: 89 ENROLLMENT STATUS: On-track trials: 62% Behind schedule: 28% Critically delayed: 10% Most competitive enrollment: Obesity, NASH, Alzheimer's UPCOMING CATALYSTS (Next 90 Days): Phase III readouts: 47 expected PDUFA dates: 12 scheduled Advisory committees: 4 scheduled STRATEGIC INSIGHTS: Decentralized trial adoption: 34% of new Phase III trials AI-assisted patient matching: reducing screening failures 25% TREND: Clinical timelines compressing — speed-to-market critical

Agent Comparison Table

All ten AI agents deployed for clinical trial monitoring and operations intelligence.

Agent NamePurposeDescriptionKey Outputs
Registry MonitorTrial DetectionMonitors clinical trial registries and competitor press pages for new trial initiations and status changesNew trial alerts, status change notifications, registry dashboards
CRO BenchmarkerVendor IntelBenchmarks CRO capabilities, performance metrics, and pricing from domain content analysisCRO scorecards, capability assessments, pricing benchmarks
Enrollment TrackerPatient RecruitmentAnalyzes enrollment dynamics across competitor trials monitoring recruitment status changesEnrollment forecasts, competition maps, bottleneck alerts
Endpoint AnalystOutcome TrackingMonitors trial endpoints, interim analyses, and topline results from press and investor pagesReadout alerts, outcome analysis, endpoint trend reports
Site OptimizerSite SelectionAnalyzes site performance data and regional capacity to optimize site network selectionSite rankings, capacity maps, activation benchmarks
Protocol TrackerDesign ChangesDetects protocol amendments from registry updates and press disclosuresAmendment alerts, design change analysis, implication assessments
Submission MonitorRegulatory FilingTracks NDA/BLA submissions, priority review designations, and PDUFA datesPDUFA calendars, submission alerts, approval probability estimates
Readout PredictorCatalyst ForecastingPredicts data readout windows from enrollment signals and conference calendarsCatalyst calendars, readout forecasts, conference predictions
Cost BenchmarkerBudget IntelligenceBenchmarks clinical trial costs from CRO disclosures and regional cost analysisCost benchmarks, regional comparisons, optimization recommendations
Clinical DashboardSynthesisAggregates all clinical trial intelligence into executive dashboardsWeekly trial briefs, catalyst calendars, competitive trial landscapes

Frequently Asked Questions

How do agents detect new clinical trials before public databases update?
Agents monitor competitor press release pages and investor presentations, which often announce trial initiations days or weeks before registry listings appear. Pipeline page updates also reveal new programs before formal registration, giving early visibility into competitive clinical development activity.
Can domain intelligence predict clinical trial data readout timing?
Agents analyze enrollment completion signals from press pages, estimated primary completion dates from registries, and conference abstract submission deadlines to predict readout windows. Investor page guidance like "topline expected H1 2026" combined with conference calendar alignment enables accurate readout forecasting.
How does enrollment competition intelligence work?
Agents track all active trials competing for the same patient population by analyzing therapeutic area, inclusion criteria signals, and site overlap. When multiple sponsors are enrolling similar patients simultaneously, agents flag enrollment competition risk and identify geographic regions with available capacity.
What CRO performance metrics can be derived from domain intelligence?
CRO capabilities, specializations, and client relationships are extracted from products pages, case studies, and press releases. Investor page disclosures reveal backlog, revenue growth, and margin trends that indicate pricing power and capacity constraints. Career page analysis reveals investment in new capabilities.
How does protocol amendment detection benefit clinical strategy?
Protocol amendments often signal trial execution challenges such as enrollment difficulties, endpoint concerns, or safety signals. Detecting competitor amendments early allows clinical teams to anticipate regulatory trends, adjust own trial designs proactively, and identify competitive vulnerabilities.

Top 10 Ways AI Agents Transform Clinical Trial Intelligence

1

Early Trial Detection

Agents detect new clinical trials from press releases and pipeline page updates days before public registry listings, providing competitive lead time.

2

Enrollment Competition Mapping

Real-time monitoring of competing trials for the same patient population prevents enrollment bottlenecks and enables strategic site selection.

3

Data Readout Forecasting

Conference calendar alignment and enrollment completion signals enable accurate prediction of competitor data readout windows for strategic planning.

4

CRO Performance Benchmarking

Domain intelligence reveals CRO capabilities, specializations, and performance metrics that inform vendor selection and contract negotiations.

5

Protocol Amendment Early Warning

Detecting competitor protocol amendments reveals trial execution challenges and regulatory trend signals that inform own program design decisions.

6

Site Network Optimization

Site performance analysis and regional capacity mapping ensure optimal site selection that maximizes enrollment speed while minimizing cost.

7

Regulatory Milestone Tracking

Automated tracking of NDA filings, PDUFA dates, and designation grants keeps clinical teams aligned with competitive regulatory timelines.

8

Endpoint Trend Analysis

Monitoring evolving endpoint acceptance and surrogate marker adoption helps trial designers align protocols with emerging regulatory expectations.

9

Clinical Cost Benchmarking

CRO pricing signals and regional cost analysis enable budget optimization and identification of cost-effective trial execution strategies.

10

Unified Clinical Intelligence Dashboard

Consolidated trial monitoring replaces manual tracking with automated, domain-sourced intelligence across thousands of competitor programs.

Get the AI Agent Database
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your Pharma AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 102M domains, 20 page types each, quarterly refreshes, and real-time change signals for pharmaceutical competitive intelligence.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.